Further analyses of the subgroups of IPSS-R and MDS subtypes demonstrated that STAG2 and RUNX1 mutations were indeed more frequent in cases at medium and high risk, respectively, while NRAS mutations were moderately associated with MDS-AML, meaning they could potentially have early diagnostic value for MDS-AML. This evidence concerns the gene RUNX1 and acute myeloid leukemia.